• 1
    Bodman KB, Roitt IM. The pathophysiology of rheumatoid arthritis. Fund Am Clin Immunol 1994; 2: 7381.
  • 2
    Guidelines for the management of rheumatoid arthritis: American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39: 71322.
  • 3
    Saag KG. Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 2002; 4: 21825.
  • 4
    Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis. Clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002; 136: 112.
  • 5
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 6
    Snell ES. The pharmacological properties of corticosteroids in relation to clinical efficacy. Br J Dermatol 1976; 94 Suppl 12: 1523.
  • 7
    Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease. Budesonide: a model of targeted therapy. Alimen Pharmaco Ther 1997; 11 Suppl 3: 98108.
  • 8
    Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 17199.
  • 9
    Oku N, Namba Y. Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst 1994; 11: 23170.
  • 10
    Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J Drug Target 1994; 2: 397403.
  • 11
    Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 98792.
  • 12
    Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001; 91: 182633.
  • 13
    Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999; 37: 22535.
  • 14
    Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, et al. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000; 41: 62230.
  • 15
    Amselem S, Gabizon A, Barenholz Y. A large-scale method for the preparation of sterile and non-pyrogenic liposomal formulations of defined size distributions for clinical use. In: GregoriadisG, editor. Liposome technology. Boca Raton, FL: CRC Press; 1993. p. 50125.
  • 16
    Rouser G, Fkeischer S, Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 4946.
  • 17
    Koga T, Pearson CM. Immunogenicity and arthritogenicity in the rat of an antigen from Mycobacterium tuberculosis wax D. J Immunol 1973; 111: 599608.
  • 18
    Derendorf H, Rohdewald P, Hochhaus G, Möllmann H. HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. J Pharm Biomed Anal 1986; 4: 197206.
  • 19
    Weusten BLAM, Jacobs JWG, Bijlsma JWJ. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 18392.
  • 20
    Wollheim FA. Acute and long-term complications of corticosteroid pulse therapy. Scand J Rheumatol Suppl 1984; 54: 2732.
  • 21
    Caldwell JR. Intra-articular corticosteroids: guide to selection and indications for use. Drugs 1996; 52: 50714.
  • 22
    Hunter JA, Blyth TH. A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders. Drug Saf 1999; 21: 35365.
  • 23
    Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 2000; 293: 9961001.
  • 24
    Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994; 1190: 99107.
  • 25
    Carol M, Pelegri C, Castellote C, Franch A, Castell M. Immunohistochemical study of lymphoid tissues in adjuvant arthritis (AA) by image analysis: relationship with synovial lesions. Clin Exp Immunol 2000; 120: 2008.
  • 26
    Storm G, Steerenberg PA, Emmen F, van Borssum Waalkes M, Crommelin DJ. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 1988; 965: 13645.
  • 27
    Van Borssum Waalkes M, Scherphof GL. Liposome-incorporated 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophages. Sel Cancer Ther 1990; 6: 1522.